OTLK Earnings

OTLK reported its earnings on 2025-08-13, showcasing a revenue of 0.00 against an estimate of 3.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.42 by 0% . The stock experienced a 14.08% price change on the earnings day and a 23.47% change over the next five days, reflecting market reactions to the results.

Following OTLK's earnings announcement on 2025-08-13, the stock price moved by 14.08% on the day of the release. Over the subsequent five days, it saw a 23.47% change. Historically, OTLK's stock price tends to shift by an average of -3.27% in the 10 days leading up to earnings and +5.60% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate OTLK’s annual revenue to reach 6.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -15.71% and EPS estimates Revise Upward by 156.67% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between OTLK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Downward by -15.71%, while EPS estimates moved Revise Upward by 156.67% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OTLK's stock price typically moves by -3.27% in the 10 days before its earnings and +5.60% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 6.00M.

The earnings call presents a mixed outlook. Positive aspects include a reduction in net loss, ongoing clinical trials, and expected EU approval. However, regulatory, clinical trial, and financial risks pose significant uncertainties. The Q&A section highlights potential delays in BLA resubmission and unclear details on UK market access, which are concerns. The absence of strong catalysts like new partnerships or record revenues tempers any positive sentiment. Thus, the overall sentiment remains neutral, as potential gains are balanced by risks and uncertainties.